Coding

Part:BBa_K3712020

Designed by: Yifan Li   Group: iGEM21_HUST2-China   (2021-10-20)
Revision as of 19:12, 20 October 2021 by Registry (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


Wild-type TLR2 antagonist

LR2 antagonist is the binding sites of TLR2 to triacylated lipoproteins, which can inhibit P.acnes surface antigen by binding to it, preventing it from binding to TLR2 on the cell surface and avoiding inflammation. We intercepted TLR2 antagonist from TLR2 and performed some site-directed mutations. The first is to shorten the beta loop to prevent triacylated lipoproteins from missing the target. Secondly, the hydrophobicity of the hydrophobic pocket was enhanced to improve the binding ability of lipoprotein. In this way, we expect to obtain an effective TLR2 antagonist with significant anti-inflammatory effects.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI.rc site found at 178


[edit]
Categories
Parameters
None